Novartis AG - Total Other Finance Cost

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Total-Other-Finance-Cost" stands at 0.7971 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 03/31/2023.

Novartis AG's third quarter result of 0.305 Billion USD for the item "Total Other Finance Cost" represents a decrease of -5.66 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of 0.305 Billion USD for the item "Total Other Finance Cost" represents an increase of 993.07 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 0.7971 Billion USD for the item "Total Other Finance Cost" represents an increase of 74.07 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 1.16 Billion United States Dollars compared to the value the year prior.
The 1 year change is 1.16 Billion United States Dollars.
The 3 year change is -14.27 Billion United States Dollars.
The 5 year change is 0.8813 Billion United States Dollars.
The 10 year change is 1.48 Billion United States Dollars.

The Serie's long term average value is 0.728 Billion United States Dollars. It's latest available value, on 09/30/2025, is 0.0687 Billion United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 12/31/2018, to it's latest available value, on 09/30/2025, is +1.73 Billion.
The Serie's change in United States Dollars from it's maximum value, on 09/30/2022, to it's latest available value, on 09/30/2025, is -14.27 Billion.